To establish the utility of serum apelin as a predictive marker for sarcopenia, additional large-scale longitudinal studies and repeated measurements over time are required to account for the dynamic nature of apelin levels and their fluctuations due to acute or chronic factors. This evidence concerns the gene APLN and sarcopenia.